Free Trial
NASDAQ:LNTH

Lantheus (LNTH) Stock Price, News & Analysis

Lantheus logo
$84.45 +0.96 (+1.15%)
As of 03:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Lantheus Stock (NASDAQ:LNTH)

Key Stats

Today's Range
$83.10
$85.31
50-Day Range
$73.86
$108.74
52-Week Range
$73.11
$126.89
Volume
509,844 shs
Average Volume
1.03 million shs
Market Capitalization
$5.84 billion
P/E Ratio
24.07
Dividend Yield
N/A
Price Target
$130.50
Consensus Rating
Buy

Company Overview

Lantheus Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

LNTH MarketRank™: 

Lantheus scored higher than 89% of companies evaluated by MarketBeat, and ranked 122nd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lantheus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lantheus has only been the subject of 2 research reports in the past 90 days.

  • Read more about Lantheus' stock forecast and price target.
  • Earnings Growth

    Earnings for Lantheus are expected to grow by 4.99% in the coming year, from $6.01 to $6.31 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lantheus is 24.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.61.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lantheus is 24.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.54.

  • Price to Book Value per Share Ratio

    Lantheus has a P/B Ratio of 5.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Lantheus' valuation and earnings.
  • Percentage of Shares Shorted

    13.60% of the float of Lantheus has been sold short.
  • Short Interest Ratio / Days to Cover

    Lantheus has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Lantheus has recently increased by 14.27%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Lantheus does not currently pay a dividend.

  • Dividend Growth

    Lantheus does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.60% of the float of Lantheus has been sold short.
  • Short Interest Ratio / Days to Cover

    Lantheus has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Lantheus has recently increased by 14.27%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Lantheus has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Lantheus this week, compared to 10 articles on an average week.
  • Search Interest

    Only 5 people have searched for LNTH on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,002,651.00 in company stock.

  • Percentage Held by Insiders

    Only 1.50% of the stock of Lantheus is held by insiders.

  • Percentage Held by Institutions

    99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lantheus' insider trading history.
Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Stock News Headlines

How a Kansas farm boy gained 1,285% in two days
A former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a meme stock. It was a pattern called “Crossfire” — a 3-step setup you can execute in a normal brokerage app. Master trader Jeff Clark is now revealing how it works in a free 30-minute video, available for a limited time.
Lantheus Seems Worth The (Very Real) Risks
See More Headlines

LNTH Stock Analysis - Frequently Asked Questions

Lantheus' stock was trading at $89.46 at the beginning of the year. Since then, LNTH stock has decreased by 4.8% and is now trading at $85.14.

Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its quarterly earnings data on Wednesday, May, 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by $0.11. The firm's revenue for the quarter was up .8% on a year-over-year basis.
Read the conference call transcript
.

Lantheus (LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Lantheus' top institutional shareholders include Reinhart Partners LLC. (2.03%), Harbor Capital Advisors Inc. (0.27%), Silverberg Bernstein Capital Management LLC (0.04%) and E. Ohman J or Asset Management AB (0.03%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Etienne Montagut, Andrea Sabens, James H Thrall, Heinz Christoph Maeusli, Gerard Ber, Brian A Markison, Gary J Pruden and Minnie Baylor-Henry.
View institutional ownership trends
.

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/07/2025
Today
7/10/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LNTH
CIK
1521036
Employees
700
Year Founded
N/A

Price Target and Rating

High Price Target
$175.00
Low Price Target
$109.00
Potential Upside/Downside
+53.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.52
Trailing P/E Ratio
24.11
Forward P/E Ratio
14.12
P/E Growth
N/A
Net Income
$312.44 million
Net Margins
16.55%
Pretax Margin
23.18%
Return on Equity
36.99%
Return on Assets
20.55%

Debt

Debt-to-Equity Ratio
0.49
Current Ratio
5.74
Quick Ratio
5.46

Sales & Book Value

Annual Sales
$1.53 billion
Price / Sales
3.83
Cash Flow
$7.30 per share
Price / Cash Flow
11.62
Book Value
$15.65 per share
Price / Book
5.42

Miscellaneous

Outstanding Shares
69,190,000
Free Float
68,148,000
Market Cap
$5.87 billion
Optionable
Optionable
Beta
0.12
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:LNTH) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners